Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
y maintains aworld-class intellectual property position in the field ...Contact: Sharon Correia ... Director Corporate Communications ... scorreia@alseres.com/... 508-497-2360 ext. 224 ...
y maintains a
world-class intellectual property position in the field of regenerative
therapeutics. Our energy and focus is reflected in several important
initiatives. Cethrin(R) is a recombinant-protein-based drug designed to
promote nerve repair after acute spinal cord injury. Cethrin has
demonstrated positive interim results in a Phase I/IIa clinical trial. The
Company's research and pre-clinical programs include, Inosine for the
treatment of spinal cord injury and stroke, Oncomodulin for the treatment
of ocular injury and disease and research programs directed at a number of
regenerative therapies including bone repair. The Company has a robust
molecular imaging development program targeting diagnosis of Parkinson's
disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular
imaging candidate, is in Phase III clinical trials for the diagnosis of
Parkinson's disease. Alseres has research collaborations with Harvard
Medical School and Children's Hospital Boston.